Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00177957 · ClinicalTrials.gov registry record
Gram Negative Bacteremia, Risk Factors for Failure of Therapy
A clinical trial of Gram-negative Bacterial Infections, sponsored by University of Pittsburgh.
- Completed
- Registry status
- 600
- Enrollment target
- 1
- Study location
NCT00177957 is a study of Gram-negative Bacterial Infections that has completed, run by University of Pittsburgh. The registered enrollment target is 600 participants, above the 292-participant average among 4 other Gram-negative Bacterial Infections trials with a reported enrollment target (105% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00177957, a study of Gram-negative Bacterial Infections, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- 600 participants
- Enrollment target
- 1
- Study location
Study Summary
The aims of this study are to: * Determine the risk factors for multidrug resistance in bloodstream isolates of Gram negative bacilli * Determine the mechanisms of multidrug resistance in bloodstream isolates of Gram negative bacilli * Determine the risk factors for failure of prompt clearance of the blood of Gram negative bacteria * Determine the survival of patients with Gram negative bacteremia * Determine if failure of prompt clearance of the blood of Gram negative bacteria is a predictor of mortality following this infection
Conditions Studied
Study Locations (1)
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2005-04 |
| Est. Completion | 2016-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00177957
The ClinicalTrials.gov registry entry for NCT00177957 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 292-participant average among 4 other Gram-negative Bacterial Infections trials with a reported enrollment target (105% higher). The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gram-negative Bacterial Infections appearing as the primary indexed condition, and to 0 interventions.
NCT00177957 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00177957 about?
NCT00177957 is a clinical study titled "Gram Negative Bacteremia, Risk Factors for Failure of Therapy". The aims of this study are to: * Determine the risk factors for multidrug resistance in bloodstream isolates of Gram negative bacilli * Determine the mechanisms of multidrug resistance in bloodstream isolates of Gram negative bacilli * Determine the risk factors for failure of prompt clearance of t...
What is the current status of trial NCT00177957?
This trial is currently completed. The enrollment target is 600 participants. The study started on 2005-04. Estimated completion is 2016-05.
What conditions does trial NCT00177957 study?
This clinical trial studies the following conditions: Gram-negative Bacterial Infections.
Who is sponsoring clinical trial NCT00177957?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00177957 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gram-negative Bacterial Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections
RECRUITING · Phase 2
-
Piperacillin as a Part of Antibiotic Streamlining in the Intensive Care Unit
COMPLETED
-
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Participants
COMPLETED · Phase 2
-
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.